Efficacy and safety of topiramate for the treatment of chronic migraine: A randomized, double-blind, placebo-controlled trial

Keyphrases

• Randomized Placebo-controlled Trial 100%
• Chronic Migraine 100%
• Topiramate 100%
• Placebo 58%
• Migrainous 23%
• Migraine 23%
• Adverse Events 17%
• Tolerability 11%
• Placebo Groups 11%
• Headache Days 11%
• Efficacy Endpoint 11%
• Upper Respiratory Tract Infection 11%
• Monthly Number 11%
• Migraine Headache Days 11%
• Nausea 5%
• Headache 5%
• Daily Dose 5%
• Clinical Trials 5%
• Maintenance Dose 5%
• Treatment Duration 5%
• Maximum Tolerated Dose 5%
• Neurological Examination 5%
• Intent-to-treat 5%
• Unmet Medical Need 5%
• Medication Use 5%
• Serious Adverse Events 5%
• Safety Assessment 5%
• Initial Dose 5%
• Acute Headache 5%
• Paresthesia 5%
• Migraine Days 5%
• Maintenance Interval 5%
• Analysis of Covariance 5%
• Change in Mean 5%
• Gatekeepers 5%
• Fixed Sequence 5%
• Moderate Severity 5%
• Spontaneous Reports 5%
• Preventive Migraine Treatment 5%
• Efficacy Assessment 5%
• Clinical Adverse Events 5%
• Routine Laboratory Parameters 5%
• Well Tolerated 5%
• Change from Baseline 5%
• Treatment-related Adverse Events 5%
• Means Reduction 5%

Pharmacology, Toxicology and Pharmaceutical Science

• Placebo 100%
• Transformed Migraine 100%
• Topiramate 100%
• Migraine 58%
• Adverse Event 35%
• Headache 11%
• Tolerability 11%
• Upper Respiratory Tract Infection 11%
• Nausea 5%
• Clinical Trial 5%
• Maintenance Dose 5%
• Maximum Tolerated Dose 5%
• Paresthesia 5%
• Efficacy Assessment 5%